Wedbush Securities’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Wedbush Securities’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,661	Closed	-$13K	–	1050
2019 Q4	$13K	Buy	+2,661	New	+$17.2K	﹤0.01%	986
2018 Q3	–	Sell	-1,600	Closed	-$14K	–	956
2018 Q2	$14K	Sell	1,600 -3,700	-70%	-$32.8K	﹤0.01%	872
2018 Q1	$47K	Sell	5,300 -1,100	-17%	-$11.3K	0.01%	784
2017 Q4	$65K	Buy	6,400 +4,900	+327%	+$59.2K	0.01%	814
2017 Q3	$23K	Sell	1,500 -3,750	-71%	-$44.3K	﹤0.01%	822
2017 Q2	$47K	Buy	+5,250	New	+$103K	0.01%	805

Other funds holding IDXG

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Wedbush Securities's IDXG Position: Q1 2020 in Review

Wedbush Securities sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2020, closing a stake of 2,661 shares — an estimated $13K sold.

Wedbush Securities first reported a position in IDXG in Q2 2017 and held it in 6 quarters. The position peaked at $65K in Q4 2017. 15 funds tracked by Wall St. Rank hold IDXG as of Q1 2020.

Wedbush Securities reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Wedbush Securities sold 2,661 Interpace Biosciences, Inc. Common Stock shares in Q1 2020, an estimated $13K.
Wedbush Securities first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2017 and held it in 6 quarters.
Wedbush Securities's Interpace Biosciences, Inc. Common Stock position peaked at $65K in Q4 2017.
15 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2020.

Based on Wedbush Securities's 13F filing for Q1 2020, filed 17 Apr 2020.